Rxsight Inc (NASDAQ:RXST) posted upbeat second-quarter sales and raised its FY24 revenue forecast on Monday. RxSight reported quarterly sales of $34.887 million which beat the analyst consensus estimate of $32.283 million by 8.07 percent, according to data from Benzinga Pro. This is a 67.65 percent increase over sales of $20.810 million the same period last year. “In the second quarter, we continued to make significant progress in the adoption of adjustability as a new standard in the premium market, highlighted by robust LDD sales and the positive reception of the recently launched LAL+,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. ...